Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: A novel target of thiazolidinediones

Circulation

Volumn 107, Issue 21, 2003, Pages 2664-2669

  Varo, Nerea ^a   Vicent, David ^b   Libby, Peter ^a,g   Nuzzo, Rebecca ^a   Calle Pascual, Alfonso L ^h   Bernal, María Rosa ^f   Fernández Cruz, Arturo ^f   Veves, Aristidis ^d   Jarolim, Petr ^h   Varo, Jose Javier ^e   Goldfine, Allison ^h   Horton, Edward ^c   Schönbeck, Uwe ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c JOSLIN DIABETES CENTER   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY OF NAVARRA   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^g HARVARD MEDICAL SCHOOL   (United States)

^h NONE

Author keywords

Atherosclerosis; Diabetes mellitus; Immunology; Inflammation

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; C REACTIVE PROTEIN; CD40 LIGAND; CELL ADHESION MOLECULE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; PLACEBO; SOLUBLE INTRACELLULAR ADHESION MOLECULE 1; STATIN; SULFONYLUREA; TRIACYLGLYCEROL; TROGLITAZONE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; FEMALE; GENDER; HUMAN; INFLAMMATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0038580675     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.cir.0000074043.46437.44     Document Type: Article

References (35)

1. Schönbeck U, Libby P. CD40 signaling and plaque instability. Circ Res. 2001;89:1092-103.
2. Schönbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001;58:4-43.
3. Kiener PA, Moran-Davis P, Rankin BM, et al. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol. 1995;155:4917-4925.
4. Mach F, Schönbeck U, Sukhova GK, et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998;394:200-203.
5. Lutgens E, Gorelik L, Daemen MJ, et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med. 1999;5:1313-1316.
6. Schönbeck U, Sukhova GK, Shimizu K, et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A. 2000;97:7458-7463.
7. Lutgens E, Cleutjens KB, Heeneman S, et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci U S A. 2000;97:7464-7469.
8. Aukrust P, Muller F, Ueland T, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999;100:614-620.
9. Schönbeck U, Varo N, Libby P, et al. Soluble CD40L and cardiovascular risk in women. Circulation. 2001;104:2266-2268.
10. Schonbeck U, Gerdes N, Varo N, et al. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation. 2002;106:2888-2893.
11. Cipollone F, Mezetti A, Porreca E, et al. Association between enhanced soluble Cd40L and prothrombotic state in hypercholesterolemia. Circulation. 2002;106:399-402.
12. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
13. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570-2581.
14. Libby P, Plutzky J. Diabetic macrovascular disease: the glucose paradox? Circulation. 2002;106:2760-2763.
15. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-47.
16. Frohlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 2000;23:1835-1839.
17. Pickup JC, Mattock MB, Chusney GD, et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40:1286-1292.
18. Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280:E745-E751.
19. Panahloo A, Yudkin JS. Diminished fibrinolysis in diabetes mellitus and its implication for diabetic vascular disease. Coron Artery Dis. 1996;7:723-731.
20. Goldstein BJ. Current views on the mechanism of action of thiazolidinedione insulin sensitizers. Diabetes Technol Ther. 1999;1:267-275.
21. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 2001;24:710-719.
22. Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1998;95:7614-7619.
23. Marx N, Sukhova G, Murphy C, et al. Macrophages in human atheroma contain PPARγ: differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. Am J Pathol. 1998;153:17-23.
24. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.
25. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679-684.
26. Diabetes and Nutrition Study Group of the Spanish Diabetes Association (GSEDNu). Diabetes nutrition and complications trial (DNCT): food intake and targets of diabetes treatment in a sample of Spanish people with diabetes. Diabet Care. 1997;20:1078-1080.
27. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabet Care. 2000;23:S4-S19.
28. Caballero AE, Saouaf R, Lim SC, et al. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism. 2003;52:173-180.
29. 3 integrin-dependent mechanism. Nat Med. 2002;8:247-252.
30. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591-594.
31. Vinik AI, Erbas T, Park TS, et al. Platelet dysfunction in type 2 diabetes. Diabet Care. 2001;24:1476-1485.
32. Graf D, Muller S, Korthauer U, et al. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol. 1995;25:1749-1754.
33. Olefsky JM. Treatment of insulin resistance with peroxisome proliferatoractivated receptor γ agonists. J Clin Invest. 2000;106:467-472.
34. Pasceri V, Wu HD, Willerson JT, et al. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation. 2000;101:235-238.
35. Marx N, Imhof A, Froehlich J, et al. Effect of rosiglitazone treatment on soluble CD40L in type-2 diabetic patients with coronary artery disease. Circulation. 2003;107:1954-1957.